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Abstract
Several carcinomas including gastric cancer have been reported to contain
Epstein‐Barr virus (EBV) infection. EBV‐associated gastric cancer (EBVaGC) is clas-
sified as one of four molecular subtypes of gastric cancer by The Cancer Gen-
ome Atlas (TCGA) group with increased immune‐related signatures. Identification
of EBV‐dependent pathways with significant biological roles is needed for
EBVaGC. To compare the biological changes between AGS gastric epithelial cells
and EBV‐infected AGS (AGS‐EBV) cells, proliferation assay, CCK‐8 assay, invasion
assay, cell cycle analysis, RT‐PCR, Western blot and ELISA were performed.
BI836845, a humanized insulin‐like growth factor (IGF) ligand‐neutralizing anti-
body, was used for IGF‐related signalling pathway inhibition. AGS‐EBV cells
showed slower proliferating rate and higher sensitivity to BI836845 compared to
AGS cells. Moreover, invasiveness of AGS‐EBV was increased than that of AGS,
and BI836845 treatment significantly decreased the invasiveness of AGS‐EBV.
Although no apoptosis was detected, entry into the S phase of the cell cycle
was delayed in BI836845‐treated AGS‐EBV cells. In conclusion, AGS‐EBV cells
seem to modulate their proliferation and invasion through the IGF signalling
pathway. Inhibition of the IGF signalling pathway therefore could be a potential
therapeutic strategy for EBVaGC.
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1 | INTRODUCTION
Gastric cancer is presented as the third highest cumulative
risk of cancers worldwide in 2012.1 To improve our understand-
ing of gastric cancer and to provide a roadmap for clinical
trials of targeted therapy, The Cancer Genome Atlas (TCGA)
group classified gastric carcinoma into four molecular sub-
types: Epstein‐Barr virus (EBV)‐positive, microsatellite instabil-
ity (MSI), genomically stable (GS) and chromosomal instability
(CIN).2
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EBV, the focus of this study, was first detected in a Burkitt's
lymphoma cell line. Since then, many studies have found EBV to be
associated with several well‐known human malignancies such as
nasopharyngeal carcinoma (NPC), Hodgkin's lymphoma and Epstein‐
Barr virus‐associated gastric cancer (EBVaGC).3,4 Incidence of
EBVaGC is reported to be approximately 10% of globally detected
gastric cancers. In addition, clinicopathological characteristics such as
undifferentiated type5 and CpG island hypermethylation6 are
reported to be high in EBVaGC. Prognosis of EBVaGC is also better
than that of EBV‐negative cases because lymph node metastasis in
EBVaGC is significantly less frequent than in EBV‐negative gastric
cancer.7
Many studies characterizing EBVaGC have been reported since
the 1990s.8 Most studies have focused on finding EBV‐specific
genes and their biological functions,9,10 related microRNAs11,12 and
chemo‐resistance mechanisms.13,14 Recently, high‐throughput assays
were attempted to uncover regulatory mechanisms in EBVaGC.15
However, only a few studies on target‐specific pathways in
EBVaGC have been reported. One report has suggested that
sequential combination is needed to improve the sensitivity of 5‐
fluororacil, one of adjuvant therapy agents in solid tumour, sensitiv-
ity when using PI3K inhibitors in EBV‐positive gastric cancer cell
lines.16
Several studies have suggested that the insulin‐like growth fac-
tor‐1 receptor (IGF‐1R) pathway is an essential target of EBV‐posi-
tive cancer such as NPC.17 IGF‐related ligands (IGF‐1, IGF‐2 and
insulin) and insulin‐like growth factor binding proteins (IGFBPs) are
produced the liver that are stimulated by growth hormone (GH).
Mainly, a complex of circulating IGFBPs and acid‐labile subunit
(ALS) prolongs the half‐life of IGF‐related ligands and delivers
them to a complete receptor. Activated IGF‐1R by IGF‐1 and
IGF‐2 plays a critical role in proliferation, migration and invasion.
Many cancers express IGF‐1R and 75.2% of stomach cancer
tissue expresses IGF‐1R, which may be the cause of poor
prognosis.18
Several IGF‐1R‐targeted drugs were developed based on the
importance of the IGF‐1R signalling pathway, but few proved to
be effective. Considerable biological restrictions of IGF‐1R are
the reasons why development of IGF‐1R pathway‐targeting
drugs has been difficult.19 The major problem of targeting IGF‐
1R lies in its sequence similarity to the insulin receptor, which
may lead to metabolic dysfunction. Mainly, insulin receptor iso-
form A (IR‐A) activated by IGF‐2 is known to promote onco-
genic signalling. To overcome blocking that action without
interfering the insulin axis insulin receptor activation, BI836845
(Xentuzumab), a drug that targets both IGF‐1 and IGF‐2, was
developed and there are many ongoing clinical trials on various
type of tumour.20
In this study, we investigated the IGF‐1R pathway and related
biological roles in EBVaGC using BI836845. We also compared bio-
logical changes after IGF‐1R signalling pathway inhibition in AGS and
AGS‐EBV cell lines.
2 | METHODS
2.1 | Materials
BI836845, a humanized IGF ligand‐neutralizing antibody, was kindly
provided by Dr. Ulrike Weyer‐Czernilofsky (Boehringer Ingelheim).
Anti‐pIGF‐1R, anti‐IGF‐1R, anti‐pAkt‐Thr308, anti‐pAkt‐Ser473, anti‐
pERK and anti‐Snail antibodies were purchased from Cell Signaling
(Danvers). Anti‐IGFBP‐3, anti‐IGFBP‐6, anti‐ERK, anti‐vimentin (Santa
Cruz Biotechnology, Dallas), anti‐E‐cadherin (BD biosciences, Franklin
Lakes) and anti‐α‐tubulin (Sigma‐Aldrich, Saint Louis) antibodies were
also purchased.
2.2 | Cell lines
Human gastric epithelial cancer cell line AGS (ATCC No. CRL‐1739)
was obtained from the American Type Culture Collection. AGS‐EBV
cell line was infected with green fluorescent protein (GFP)‐tagged
EBV made from Akata cells21 (Supplementary 1A and B). AGS cells
were maintained in EMEM supplemented with heat‐inactivated 10%
foetal bovine serum containing 100 Units/mL penicillin and 100 μg/
mL streptomycin. AGS‐EBV cells were cultured in the same culture
medium with the addition of 400 μg/mL G418 (A.G. Scientific, San
Diego). Cells were incubated at 37°C in a humidified atmosphere of
5% CO2.
2.3 | Proliferation assay
For proliferation assays, 2.0 × 103 cells were seeded in 24‐well
plates. The wells were filled with fresh media and 10 μg/mL
BI836845 the day after seeding and repeated every 3 days. Samples
from triplicate wells were harvested every day, and cells were
counted after Trypan blue staining. Growth curves were plotted as
cell numbers versus time.
2.4 | Cell viability
Cell viability was determined using a Cell Counting Kit‐8
(Dojindo, Kumamoto, Japan) according to the manufacturer's
instructions. Briefly, 5.0 × 104 cells were seeded in 96‐well plates
and incubated for 24 hours. Serial diluent of BI836845 (0, 0.01,
0.1, 1, 10, 100 μg/mL) was treated to each well for 72 hours.
Next, 10 μL of CCK‐8 solution was added to each well and
incubated for 2 hours at 37°C. Absorbance was determined at
450 nm using microplate reader (TECAN, Männedorf, Switzerland).
2.5 | Invasion assay
Trans‐well invasion chambers were pre‐coated with 500 ng/mL
Matrigel (Corning, Corning, USA) for 6 hours. The medium at the
bottom of the 24‐well plate was replaced with fresh medium con-
taining 10% FBS, and 2 × 104 cells in serum free media were added
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to the top chamber. After incubation for 24 hours at 37°C, the cells
were then fixed with 4% formaldehyde for 2 minutes. The chambers
were then washed with PBS and stained with 1% crystal violet for
10 minutes. After cleaning and drying the chamber membrane, cells
were counted using an inverted microscope (Zeiss, Oberkochen,
Germany).
2.6 | RT‐PCR
Total RNA was isolated using Trizol (Thermo Fisher Scientific, Wal-
tham) according to the manufacturer's instructions. Total RNA (2 μg)
was used for reverse transcription with Superscript II reagent kit
(Invitrogen, Carlsbad). IGF‐1R, IGF‐1, IGF‐2, IGFBP‐3, IGFBP‐6 and
glyceraldehyde‐3‐phosphate dehydrogenase (GAPDH) primers were
designed as follows: IGF‐1R forward, 5′‐TACAACTACGCCCTGGT-
CATC‐3′, and reverse, 5′‐CTTCTCACACATCGGCTTCTC‐3′; IGF‐1
forward, 5′‐CTGGAGATGTATTGCGCACC‐3′, and IGF‐1 reverse, 5′‐
CTTGTTGGTAGATGGGGGCTG‐3′; IGF‐2 forward, 5′‐ TCCCCTGA
TTGCTCTACCCA ‐3′, and IGF‐2 reverse, 5′‐TTCCGATTGCTGGC-
CATCTC‐3′; IGFBP‐3 forward, 5′‐AAGACAGCCAGCGCTACAAAG‐3′,
and IGFBP‐3 reverse, 5′‐ TACGGCAGGGACCATATTCTG‐3′; IGFBP‐
6 forward, 5′‐ ATGCCGTAGACATCTGGACTCA‐3′, and IGFBP‐6
reverse, 5′‐ AGAAGCCTCGATGGTCACAATT‐3′; and GAPDH for-
ward, 5′‐CCATGGAGAAGGCTGGGG‐3′, and reverse, 5′‐CAAAGT
TGTCATGGATGACC‐3′. PCR was performed on a thermal cycler
(Eppendorf, Hamburg, Germany) using the appropriate annealing
temperature. PCR products were examined using agarose gel elec-
trophoresis and exposed to a UV detector to confirm the presence
of a single amplification product.
2.7 | ELISA
Concentration of IGF‐1 and IGF‐2 was measured using human ELISA
kit (Abnova, Taipei City, Taiwan) according to the manufacturer′s
instructions. For the sample preparation, 2.5 μg of total lysate pro-
tein and 5 μg of total secreted protein were quantified by BCA
assay. Finally, concentration of IGF‐1 and IGF‐2 was calculated at
450 nm using a microplate reader.
2.8 | Western blotting
For Western blotting, control and BI836845‐treated cells were col-
lected 24 hours after treatment. A total of 30 μg of whole cell
protein extracts in RIPA lysis buffer were size‐fractionated using
10% SDS polyacrylamide gel electrophoresis and transferred to a
polyvinylidene difluoride membrane (Bio‐Rad, Hercules). Mem-
branes were blocked with 5% non‐fat dry milk/TBS‐T for 1 hour at
room temperature and then incubated overnight with primary anti-
bodies at 4°C. Membranes were washed five times with TBS‐T and
incubated with horseradish peroxidase‐conjugated secondary anti-
body for 1 hour at room temperature. Blots were washed five
times again, and protein signals were enhanced and detected using
a chemiluminescence detection kit (Santa Cruz, Dallas). The
intensity of the bands was normalized using α‐tubulin with ImageJ‐
based quantification.
2.9 | Flow cytometry
For apoptosis analysis, 5 × 105 cells were seeded in 6‐well plates
and incubated for 24 hours at 37°C in an incubator. BI836845 was
directly added to the wells, and cells were incubated for 24 hours
and 48 hours and collected in 15 mL tubes. After PBS washing, cells
were double‐stained with recombinant Pacific blue‐conjugated
Annexin V and propidium iodide (PI). Cells were gently vortexed and
incubated for 15 minutes at room temperature in the dark. Flow
cytometry analysis was performed using a FACS LSRII (BD
biosciences, Franklin Lakes) with CellQuest software. Ten thousand
single cells were gated and analysed for apoptosis.
Cell cycle analysis was performed in two different conditions. In
the first condition, ordinary cell cycle analysis was performed. Cells
were seeded in 60‐mm2 dishes and incubated in media with or with-
out BI836845 after 24 hours. After further incubation for 24 and
48 hours, cells were harvested. In the second condition, cells were
synchronized in G0/G1 phase after culturing in confluent monolayers
under serum starvation during 48 hours. After starvation, wells were
incubated with 10% FBS‐containing media, and 10 μg/mL BI836845
was added to each well. Cells harvested immediately after the
48 hours of serum starvation were labelled 0 hours; additional ali-
quots were harvested at the indicated time‐points. Cells harvested at
either the first or the second condition were fixed in cold 70% etha-
nol for more than 24 hours and stained with PI (BD biosciences,
Franklin Lakes. DNA contents were determined using FACS LSRII
(BD biosciences), and gated 20,000 events/sample were collected for
cell cycle analysis.
2.10 | Statistical analysis
Continuous data were analysed using the Student t test. Differences
were considered statistically significant when P < 0.05. The signifi-
cance of dose‐ or time‐dependent change was calculated by two‐
way ANOVA with the use of IBM SPSS statistics.
3 | RESULTS
3.1 | Expression of IGF‐related genes and proteins
in EBVaGC
To evaluate IGF‐related gene and protein expression, the baseline
expression levels in AGS and AGS‐EBV cells were first determined.
Comparing AGS and AGS‐EBV cells, no significant differences in the
mRNA levels of IGF‐1R, IGF‐1, IGF‐2 and IGFBP‐6 were observed.
Interestingly, IGFBP‐3 mRNA levels in AGS‐EBV cells were
74.6 ± 28.8%, which was higher than those in AGS cells (Figure 1A).
Western blot analysis showed that, although total IGF‐1R protein
levels in AGS‐EBV were 17.4 ± 28.8% lower than those in AGS cells,
phospho‐IGF‐1R levels were 38.9 ± 28.1% higher than those in AGS
JEONG ET AL. | 5901
cells (Figure 1B). In addition, IGFBP‐3 and IGFBP‐6 levels in AGS‐
EBV were 10.6 ± 16.9% and 27.9 ± 3.0% lower, respectively, than in
AGS cells.
To compare the expression levels of ligands, lysate and secreted
IGF‐1 or IGF‐2 were measured using ELISA (Figure 1C and D). In
AGS and AGS‐EBV, lysate IGF‐1 levels were similar, while lysate
IGF‐2 levels were 49.9 (95% confidence interval [CI]: 28.4‐71.4) and
90.3 (95% CI: 53.7‐126.9) pg/mL, respectively (Figure 1C). In con-
trast, secreted IGF‐1 levels increased when EBV was present, from
52.3 to 85.4 pg/mL. Secreted IGF‐2 levels in AGS and AGS‐EBV cells
were similar (Figure 1D). While no significant differences were
observed between AGS and AGS‐EBV, AGS‐EBV generally showed
higher expression of lysate IGF‐2 and secreted IGF‐1.
The results show that IGFBP‐3, secreted IGF‐1 and lysate IGF‐2
expression levels were increased, and phospho‐IGF‐1R was more
activated, in AGS‐EBV cells. With the exception of the aforemen-
tioned factors, the expression levels of most IGF‐related factors
were decreased in AGS‐EBV.
3.2 | Effect of BI836845 on proliferation, sensitivity
and invasion of AGS and AGS‐EBV cells
To evaluate the effect of EBV infection on AGS cells, proliferation
assay was first performed. On days 6 and 7, proliferating AGS cells
were at significantly higher number than AGS‐EBV cells (P < 0.01
and P < 0.001 at days 6 and 7, respectively; Figure 2A). We then
evaluated the effect of BI836845 on proliferation. Interestingly, no
significant difference was observed in AGS cell proliferation between
the control and BI836845‐treated groups. In contrast, proliferation
of AGS‐EBV cells was significantly inhibited by 10 μg/mL BI836845
treatment (Figure 2A). Also, cell viability of AGS and AGS‐EBV cells
in the presence of BI836845 was evaluated 72 hours post‐treat-
ment. The results show that AGS cells were not sensitive to the
BI836845 treatment, whereas AGS‐EBV cells exhibited significant
dose‐dependent inhibition (Figure 2B).
We also performed in vitro invasion assay using trans‐well cham-
bers to determine whether EBV infection is associated with invasive-
ness of gastric cancer cells. The results show that the number of
AGS and AGS‐EBV cells that had invaded through the membrane of
the trans‐well chamber was 175.0 ± 36.0 and 259.0 ± 40.6 cells/well,
respectively (P = 0.055), indicating that AGS‐EBV increased their
baseline invasiveness compared to AGS cells. We then determined
the effect of BI836845 treatment on invasiveness of both AGS and
AGS‐EBV cells. AGS cells in the treatment group showed increased
invasiveness compared to the AGS control group, particularly at
10 μg/mL BI836845 (P < 0.05). In contrast, AGS‐EBV cells presented
reduced invasiveness in a dose‐dependent manner, with a significant
reduction at 100 μg/mL BI836845 (P < 0.001) (Figure 2C,D).
In summary, EBV infection inhibited cell proliferation and cells
became sensitive to BI836845. Moreover, EBV infection led to
increased invasiveness which in turn was suppressed by BI836845
treatment.
3.3 | Effect of BI836845 on mRNA and protein
expression of IGF‐related factors and
epithelial‐mesenchymal transition (EMT) markers
We determined the effect of BI836845 on IGF‐ and EMT‐related
protein and gene expression levels in AGS and AGS‐EBV cells. In
BI836845‐treated AGS cells, mRNA expression levels of IGFBP‐6
F IGURE 1 mRNA and protein
expression of IGF‐related factors on AGS
and AGS‐EBV. (A) mRNA expression was
measured by RT‐PCR. All factors were
normalized by GAPDH and divided by AGS
expression level for relative quantification
with SD (B) Quantification of protein
expression was evaluated by Western blot.
All factors were normalized by α‐tubulin,
and AGS cell line was used as a control.
The factors were represented as mean ±
S.D (C) IGF‐1 and IGF‐2 in 2.5 μg of total
lysate protein was measured by ELISA. (D)
Secreted IGF ligands were quantified in
5 μg of total protein. IGF‐1 and IGF‐2
expressed with mean with 95% confidence
interval. Statistical significance is
represented in relation to control: AGS
versus AGS‐EBV; *P < 0.05, ***P < 0.001
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were increased, whereas no change was observed in the expression
levels of all the other factors. In contrast, in BI836845‐treated AGS‐
EBV cells, a decrease in mRNA expression levels of IGF‐1, IGFBP‐3
and IGFBP‐6 was observed (Figure 3A).
As can be seen in Figure 3B, phospho‐IGF‐1R levels were mark-
edly reduced after BI836845 treatment in both AGS and AGS‐EBV
cells. Lysate IGFBP‐3 levels in AGS‐EBV cells also decreased after
BI836845 treatment. Comparison between AGS and AGS‐EBV cells
showed that IGFBP‐3 was secreted only in AGS cells. In addition, no
changes in expression patterns were observed in the other factors
after BI836845 treatment.
Even though total Akt levels were not changed after EBV infec-
tion, total ERK levels decreased (Figure 3C). No changes in phospho‐
Akt (T308) or phospho‐ERK levels were observed between AGS and
AGS‐EBV cells after BI836845 treatment. However, phospho‐Akt
(S473) levels were generally reduced post‐treatment. In addition,
phospho‐Akt (S473) levels in the AGS‐EBV treatment group
decreased to a higher extent than those in the AGS treatment group
(Figure 3C).
These results indicate that blocking IGF‐1 and IGF‐2 with
BI836845 leads to inhibition of the IGF‐1R signalling pathway
through control of IGFBPs IGFBP‐3 mRNA and secreted IGFBP‐6). In
addition, IGFBP‐3 and IGFBP‐6 secretion may be a part of defence
mechanism, and secreted IGFBPs prolonged half‐life of IGF‐1 and
IGF‐2, against blocking IGF‐1 and IGF‐2 in AGS cells. Moreover,
downstream pathway inhibition was related with activation of Akt
(S473).
To investigate the expression levels of intracellular EMT‐related
molecules, which are associated with the ability for invasion, we
examined the protein expression of E‐cadherin, Snail and vimentin.
Despite the very low E‐cadherin levels observed, no significant dif-
ferences were detected between the control and BI836845‐treated
groups. Snail, which inhibits the activation of E‐cadherin, showed
higher expression levels in AGS than in AGS‐EBV cells. In addition,
neither AGS nor AGS‐EBV treatment groups showed any changes in
Snail levels after treatment. Compared to both control groups,
vimentin expression levels in AGS‐EBV were reduced after
BI836845 treatment, whereas those in AGS remained unchanged
(Figure 3D).
Vimentin expression was down‐regulated after BI836845 treat-
ment in AGS‐EBV but not in AGS cells. We hereby conjectured that
the ability to invade may be regulated by vimentin expression in
AGS‐EBV cells independently of E‐cadherin and Snail.
3.4 | Apoptosis or cell cycle arrest was not
observed after BI836845 treatment in AGS‐EBV
We performed Annexin V/PI double‐staining assay to determine
whether the reduction in cell viability was induced by apoptosis. As
shown in Figure 4A, the proportion of cell death in AGS‐EBV cells
was approximately 4 times greater than that in AGS cells. Neither
AGS nor AGS‐EBV cells showed any increment in apoptosis after
treatment with 10 μg/mL BI836845.
When we performed cell cycle analysis using PI staining, no sig-
nificant cell cycle arrest was observed in AGS and AGS‐EBV cells
after BI836845 treatment (Figure 4B). Baseline sub‐G1 proportion
was approximately 1.0% for both cell lines (AGS and AGS‐EBV).
Specifically for AGS‐EBV, both control and BI836845 treated group
increased to a 3.0% sub‐G1 proportion at 48 hours.
These results indicate that the reduction in proliferation in AGS‐
EBV compare to AGS may be influenced by the increase in natural
cell death. However, inhibition of proliferation and cell viability in
BI836845‐treated AGS‐EBV cells resulted neither from apoptotic cell
death nor from cell cycle arrest.
F IGURE 2 Phenotypic changes in AGS
and AGS‐EBV cells after treatment with
BI836845. (A) Proliferation of AGS and
AGS‐EBV cells was determined with
Trypan Blue exclusion assays for 7 days.
(B) BI836845 sensitivity was measured
using CCK‐8 assays after 72 h. (C)
Representative crystal violet staining
images of AGS and AGS‐EBV cells. (D)
Invasive cells were counted in eight fields
of three different wells. Results were
normalized to control and are shown as
mean ± SD Statistical significance is
represented in relation to control: AGS
versus AGS‐EBV, *P < 0.05, ***P < 0.001;
AGS‐EBV versus AGS‐EBV treatment,
††P < 0.01, †††P < 0.001
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3.5 | BI836845 inhibits progression of AGS‐EBV
cells into S phase
To further investigate the possible mechanism of proliferation inhibi-
tion, we performed cell cycle analysis with G0/G1 synchronization
using serum starvation, because no cell cycle arrest could be
observed in normal culture conditions. After synchronization, the
G0/G1 proportion in AGS and AGS‐EBV cells was 62.0% and 58.2%,
respectively. Interestingly, cell cycle progression of AGS‐EBV cells
was faster than that of AGS cells (Figure 5A).
After 24 hours of G0/G1 phase synchronization, the transition
from G0/G1 to S phase increased from 30.2% to 34.7% during
BI836845 treatment in AGS cells. No other significant differences in
cell cycle progression were subsequently observed between control
and BI836845‐treated groups. In contrast, cell cycle progression
from G0/G1 to S phase after 32 hours was delayed, increasing from
29.9% to 41.3% during BI836845 treatment in AGS‐EBV cells. This
delay in cell cycle progression was continuously maintained for 40
and 48 hours in the treated AGS‐EBV cells (Figure 5B).
These results indicate that the inhibition of cell proliferation and
reduction in cell viability in treated AGS‐EBV cells may result from a
delayed cell cycle progression into S phase.
4 | DISCUSSION
To optimize genome replication, most viruses manipulate the host
cell environment and the cell cycle. Many of the EBV‐specific viral
factors were identified due to their functional impact on various cell
types.22,23 Most of these studies, however, limited their focus to
viral gene expression and their function. In our study, we extend our
focus to the biological changes in gastric cancer cells after EBV
infection and also on possible target signalling pathways.
The EBV‐infected gastric cancer cell line (NUGC‐3) and EBV‐
positive NPC cell line showed increased IGF‐1 mRNA and secreted
IGF‐1 levels compared to parental cell lines, which suggest that IGF‐
1 mediates cell proliferation.17,24 In our results, IGF‐1 mRNA levels
did not increase, although secreted IGF‐1 levels increased in AGS‐
EBV cells (Figure 1C). As well known, secreted IGF‐1 stimulates IGF‐
1R phosphorylation. Although the mRNA and protein expression
levels of most genes we examined were down‐regulated in AGS‐EBV
cells, phospho‐IGF‐1R levels were increased in AGS‐EBV cells. When
EBV infects cells, it regulates growth of the host cell and activates
selective pathways to increase the efficiency of viral factor synthe-
sis.25,26 Our results suggest that EBV may use the IGF‐1R pathway
to adapt to the host environment in the AGS cell line.
F IGURE 3 Expression of IGF‐related
genes and proteins was determined using
RT‐PCR and Western blotting, respectively.
(A) mRNA expression levels of IGF‐relates
genes were detected and normalized with
GAPDH. (B) Protein expression levels of
IGF‐related factors were measured. (C)
Expression levels of downstream factors of
the IGF‐1R signalling pathway were
determined. (D) Protein expression levels
of Snail and Vimentin, representative
epithelial–mesenchymal transition markers,
were measured using Western blotting. ‐,
Control without BI836845 treatment; +,
treatment with 10 μg/mL BI836845 for
24 h
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BI836845 treatment of AGS and AGS‐EBV cells resulted in
reduced levels of phospho‐IGF‐1R and phospho‐AKT, with greater
reduction in AGS‐EBV cells. Secreted IGFBP‐3 and IGFBP‐6 levels
were particularly increased in the AGS treatment group. Circulating
IGFBPs are known to increase IGF‐1 and IGF‐2 stability and trans-
port in the tissue, and IGFBP‐3 and IGFBP‐6 stabilize IGF‐1 and IGF‐
2, respectively.27 In our experiments, resistance to BI83685 in AGS
cells was observed in concordance with increased IGFBP‐3 and
IGFBP‐6 secretion.
Levels of mRNA or cytosol IGFBPs are associated with tumour
aggressiveness, and the underlying mechanisms are complex and
include both IGF‐dependent and IGF‐independent pathways.28 In our
results, we observed that IGFBP‐3 mRNA levels were greatly
increased in AGS‐EBV cells (Figure 1A). IGFBP‐3 is known to have
various binding partners and is associated with different cellular
functions.29 Several studies have reported an association of elevated
mRNA expression levels of IGFBP‐3 with cell growth inhibition,
namely in breast and prostate cancer cell lines. These mechanisms
are mediated by IGF‐independent pathways.30-32 In our result,
IGFBP‐3 mRNA expression was reduced only in the AGS‐EBV treat-
ment group. IGF‐independent cell death by IGFBP‐3 mRNA regula-
tion may be increased by EBV infection, which in turn increases IGF
dependence and BI836845 sensitivity on AGS‐EBV treatment group.
We also observed that while cell cycle progression was faster in
AGS‐EBV cells compared to that of AGS cells, cell proliferation was
in fact slower in AGS‐EBV (Figures 2A and 4A). The number of
necrotic AGS‐EBV cells was increased by fourfold compared to AGS
cells. Abnormal regulation by the virus or increment of nuclear
IGFBP‐3 level (Supplementary 2) may lead to natural cell death, and
this regulation conjectured to cause slower proliferation rate of
AGS‐EBV. Although the experiment was tested on different type of
cancer (bone osteosarcoma), accumulation of nuclear IGFBP‐3
F IGURE 4 Apoptosis and cell cycle analyses during BI836845 treatment of AGS and AGS‐EBV cells. (A) Apoptotic cell death was measured
at 24 h and 48 h using Annexin V/propidium iodide (PI) double staining and FACS. (B) Cell cycle analysis of unsynchronized AGS and AGS‐EBV
cells was conducted during 24 h and 48 h with PI staining using FACS. Both AGS and AGS‐EBV cells were treated with 10 μg/mL BI836845
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induced apoptosis with proteolysis.33 In our results, inhibition of pro-
liferation did not occur as a result of apoptosis or cell death in AGS‐
EBV cells treated with BI836845 (Figure 2B and 4A‐B), but from a
delay in entering the S phase of the cell cycle (Figure 5B). One study
reported similar blocking of IGF‐1R signalling activation that induced
cytostatic effects in colorectal cancer cells. Although the cancer cell
line model is different from our study, blocking the IGF signalling
pathway using tyrosine kinase inhibitors may have effects similar to
those described in this work.34
In contrast to the increased baseline invasiveness of AGS‐EBV
cells compared with AGS cells, (Figure 2C‐D), expression of EMT
markers was reduced in AGS‐EBV cells (Figure 3D). EBV infection
of AGS cells led to suppression of most baseline protein expres-
sion, a common characteristic of virus‐infected cells. Particularly,
expression of EMT‐related molecules has been shown to be regu-
lated by EBV‐specific molecules.35 In our result, mRNA levels of
IGFBP‐6 in AGS cells increased when treated with BI836845 (Fig-
ure 3A), and AGS cells treated with 10 μg/mL of BI836845 showed
3 times higher ability for invasion than the control group
(Figure 2D). In contrast, mRNA level of IGFBP‐6 in AGS‐EBV was
decreased after BI836845 treatment. Interestingly, high mRNA level
of IGFBP‐6 promotes cancer migration and invasion in an IGF‐inde-
pendent manner.36
It has been shown that IGF‐1‐dependent secretion of IGFBP‐3
induces angiogenesis and positively regulates the expression of pro‐
angiogenic molecules.37 In our results, IGFBP‐3 secretion was only
observed in treated AGS cells and their invasion to the microenvi-
ronment was increased compared to AGS‐EBV. IGFBP‐3 and IGFBP‐
6 have very complex IGF‐dependent and IGF‐independent functions,
which remains mostly unclear. EBV‐infected AGS cells may regulate
their growth and invasiveness using IGFBP‐3 and IGFBP‐6 inside and
outside cells. Inhibition of vimentin expression, independent of other
EMT proteins Snail and E‐cadherin, was observed in the AGS‐EBV
treatment group (Figure 3D). This suggests that vimentin might play
an independent role in the regulation of AGS‐EBV cell invasiveness.
As mechanistic studies of IGFBP‐3 and IGFBP‐6 were not accom-
plished in our study, future studies will be needed to evaluate the
intra‐ and extracellular functional activity.
F IGURE 5 AGS and AGS‐EBV cells were synchronized to G0/G1 to evaluate cell cycle delay. (A) To compare changes in cell cycle
progression, synchronized AGS and AGS‐EBV cells are shown in 3D charts. (B) Cell cycle progression was evaluated using propidium iodide
staining of synchronized AGS and AGS‐EBV cells. Both AGS and AGS‐EBV cells were harvested after 48 h of synchronization at 0, 12, 24, 32,
40 and 48 h. + (FBS), unsynchronized control cells at 0 h; ‐ (FBS), synchronized cells without BI836845 treatment at 0 h; C, Control without
BI836845 treatment; T, treatment with 10 μg/mL BI836845
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In our study, we demonstrated that the IGF‐1R‐related pathway
dependency of both proliferation and invasion was changed by EBV
infection in a gastric cancer cell line. Moreover, EBV‐infected cancer
cells became sensitive to BI836845. Also we suggested that regula-
tion of IGFBP‐3 and IGFBP‐6 had important roles on proliferation
and invasion of EBVaGC. Our results suggest that although limited
in scope due to validation in a single EBV‐infected gastric cell line,
IGF‐1R pathway inhibition might be an effective therapeutic target
in EBVaGC.
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